


www.epa.gov

Introduction and Background


Developmental Neurotoxicity (DNT) guideline studies

- Epidemiological. studies have indicated that developmental exposure to environmental chemicals is associated with developmental disorders
- With > 30,000 chemicals in commerce, < 200 chemicals have been tested in EPA and/or OECD guideline DNT studies.
- Current guideline developmental neurotoxicity (DNT) studies are costly, timeconsuming, use large numbers of animals and are subject to methodological and scientific uncertainties.
- Only 12 recognized human developmental neurotoxicants. (Grandjean and Landrigan,



New approach methodologies (NAMs)

• To address this gap, a suite of DNT NAMs has been proposed for screening and prioritization.



Evaluating the performance of the DNT-NAMs using sensitivity and specificity

- True Negative Rate (specificity) = True negatives/Known Negatives
- True Positive Rate (sensitivity) = True positives/ Known Positives

Results

from an

in vitro

NAM

es y) =	"Truth" or "What is known"		
S	Known negatives	Known positives	
Negatives	True negatives	False negatives	
Positives	False positives	True positives	


Problem: a curated list of negative DNT reference compounds does not currently exist

- To evaluate the performance of this battery of *in vitro* assays, we must first establish a set of DNT reference chemicals.
- DNT positive compounds were vetted in Mundy et. al. (2015)
- DNT negative compounds have not yet been vetted.

Therefore, the aim of this study is to develop a curated list of negative DNT reference chemicals.

An expert-driven literature review of "negative" reference chemicals for developmental neurotoxicity (DNT) assay evaluation Melissa M. Martin¹, Nancy C. Baker³, William K. Boyes², Kelly E. Carstens¹, Megan E. Culbreth¹, Mary E. Gilbert², Joshua A. Harrill¹, Johanna Nyffeler¹, Stephanie Padilla¹, Katie Paul Friedman¹, and Timothy J. Shafer¹

¹ Center for Computational Toxicology & Exposure, U.S. EPA, Research Triangle Park, NC 27711, USA ² Center for Public Health and Environmental Assessment, U.S. EPA, Research Triangle Park, NC 27711, USA ³ Leidos, Research Triangle Park, NC 27711, USA



U.S. Environmental Protection Agency Office of Research and Development


Methods

				Results			
	"favorable [®] profile	" or	"conditionally	Favorable compounds are not more likely to pregnancy category A or B	be U.S		
				U.S. FDA Pregnancy Category			
idence fo				Determination A B C D	Х		
there are	13%	\mathbf{D}	$1 \bigcirc 0 \land 0$		0		
negative			Conditionally	Conditionally			
o clear r, caveats			favorable = 2	5 <u>favorable 0 9 2 2</u> Not favorable 0 0 2 0	0		
tal design ertainties		6%	■ Not favorable = 5		Z		
they may				Identified ca	veats		
e studie				Group 1: Lack of data; putative negatives have limited in vivo data reported	roup 2: I		
enicillin VK			Acetaminophen	Group 1a: May suggest lack of DNT •	Caveat I:		
inst Gram positi	ve bacteria; inhibits the		cation used to treat fever and provide pain relief	Caveat A: Only one in vivo study and it suggests lack	potency a		
,	sis, leading to cell lysis revent bacterial	endo	nanism of action: selective COX-2 inhibitor; also modulates cannabinoid system via TRPV1 and CB1 receptors	 of neurodevelopmental effects Caveat B: Conflicting evidence in favor of lack of 	activate t but only a		
en/Strep) F study		deve	endocannabinoid system is present during early brain lopment and is important for cell proliferation, neuronal	neurodevelopmental effects •	Caveat J:		
s on gut microbiota, i	increases cytokine expression in r integrity and alters behavior:	• Over	ation, and axonal and neurite outgrowth 20 clinical and preclinical studies reported that	Group 1b: May suggest DNT	indirect a pituitary-		
	increased aggression (Leclercq, <i>et</i> .		nminophen produces adverse neurodevelopmental omes	 Caveat R: Compound is known to interact with a neurodevelopmentally relevant biological substrate 	Caveat K		
as a negative refe	erence chemicals,	-	Increases the risk of attention-deficit hyperactivity, hyperkinetic, or autism spectrum disorders and impairs emotional and communication skills (Viberg, e al., 2014; Philippot, et. al., 2017).		studies w of patient		
re confounded o	due lack of replicated or ffects (gut-brain axis), and	-	Produces changes in DNA methylation (Gervin, et. al. 2017), alters levels of BDNI in the cortex and striatum (Viberg, et. al., 2014, Blecharz-Klin, et. al., 2018), and		exposure		
culture media. ation = Conditio i	nally Exverable		modulates serotonergic, noradrenergic, and dopaminergic neurotransmission (Blecharz-Klin, et. al. 2017).	Caveat D: Conflicting evidence in favor of neurodevelopmental effects	Caveat L:		
		• Cate	gorical determination = Not Favorable	Caveat E: Reported effects, but not replicated or	negative		
3	DTXSID		Categorical	convincing	A com		
			determination	Group 1c: Complete lack of in vivo data with reasons for concern (potential in vivo database			
0-2	DTXSID2020		Not favorable	gaps identified).			
78-0 3-4	DTXSID3037 DTXSID4022		Conditionally favorable Conditionally favorable	Caveat F: Complete lack of literature or evidence			
2-7	DTXSID4022		Conditionally favorable	 Caveat G: No evidence for neurodevelopmental effects or evidence of concern, but evidence of acute 			
	DTXSID5020		Conditionally favorable	neurotox.			
9-9	DTXSID3052	2484	Conditionally favorable	 Caveat H: A positive DNT outcome was reported for a different salt form of the compound. 			
84-7	DTXSID2022	2707	Conditionally favorable				
86-2	DTXSID1037	7197	Conditionally favorable				
0-4	DTXSID2020		Conditionally favorable		·		
2-8	DTXSID4020		Conditionally favorable	All compounds that had one or more caveat in	C		
6-6	DTXSID1047		Conditionally favorable	groups 2 and/or 3 also had caveat(s) in group 1	က်		
)-4 6-6	DTXSID5023 DTXSID8020		Conditionally favorable Conditionally favorable	Group 1 Group 2	Antibiotics		
-70-0	DTXSID7034		Favorable		utibi		
5-8	DTXSID1023		Favorable		Ā		
0-7	DTXSID7020)552	Conditionally favorable		/		
7-8	DTXSID4022	2991	Conditionally favorable		E		
35-6	DTXSID5023	3039	Conditionally favorable		S		
73-4	DTXSID3020		Conditionally favorable		Drugs		
3-8	DTXSID4031		Conditionally favorable				
-5 3-6	DTXSID9020 DTXSID1024		Favorable Conditionally favorable				
27-1	DTXSID1024		Favorable		Food S		
5-3	DTXSID8020		Not favorable		Metal I		
-7	DTXSID5020		Favorable				
11-6	DTXSID6045	5165	Conditionally favorable	0	Other		
4-9	DTXSID2023	3270	Conditionally favorable		ı d		
51-1	DTXSID2023		Not favorable		(
65-3	DTXSID5023		Not favorable	Group 3	Pesti-		
58-6	DTXSID6021		Favorable		cide (
8-9 5-2	DTXSID7021 DTXSID5021		Conditionally favorable				
0-2 7-2	DTXSID5021		Conditionally favorable Favorable				
-2 52-0	DTXSID9044		Favorable				
2-1	DTXSID3044		Conditionally favorable	A set of 38 candidate negative compounds were evaluated using	ງ the Abs		
9-5	DTXSID6021		Conditionally favorable	• The panel determined that 8 out of 38 compounds could be cate	•		
-8	DTXSID7023		Conditionally favorable	for use in a DNT reference chemical set. 24 compounds were de			
-2	DTXSID5023	3742	Not favorable	 This reference chemical set may be customized to support performance work suggests that additional approaches to DNT NAM performance 			

2554/P115

March 22nd, 2021 01:00 PM – 02:45 PM Society of Toxicology Annual Meeting

Melissa Martin I martin.melissa@epa.gov



Conclusion

bstract Sifter Excel-based application to identify relevant studies which were then reviewed by a panel of experts. ed as "favorable" negative DNT reference compounds, whereas 6 compounds were categorized as "not favorable" ned to be "conditionally favorable" given that one or more caveats were identified. ice evaluation of specific DNT NAMs, depending on the assay principle and key processes included. Further, this valuation may be required.